Wesselius-de Casparis A, Thiery M, Yo le Sian A, Baumgarten K, Brosens I, Gamisans O, Stolk J G, Vivier W
Br Med J. 1971 Jul 17;3(5767):144-7. doi: 10.1136/bmj.3.5767.144.
A double-blind placebo-controlled multicentre study with ritodrine, a beta-mimetic uterine relaxant, has been performed in 91 patients in premature labour. All patients were treated according to a fixed dosage scheme consisting of an intravenous infusion followed by oral tablets for a total of seven days. Ritodrine arrested premature labour in 80%, the placebo in 48% of the patients (P=0.02). This short treatment, however, was usually not sufficient to prolong gestation till term. Apart from a slight to moderate rise in maternal heart rate and a slight rise in systolic blood pressure, ritodrine did not give rise to any maternal or fetal side effects. The problems of patient selection and of evaluation of the results are discussed.
一项使用β-拟交感神经子宫松弛剂利托君进行的双盲安慰剂对照多中心研究,纳入了91例早产患者。所有患者均按照固定剂量方案进行治疗,先静脉输注,随后口服片剂,共治疗7天。利托君使80%的患者早产停止,安慰剂组为48%(P=0.02)。然而,这种短期治疗通常不足以将妊娠期延长至足月。除了母体心率轻度至中度升高和收缩压略有升高外,利托君未引起任何母体或胎儿副作用。文中讨论了患者选择和结果评估的问题。